Best Spectives Podcasts (2025)

1
E136: Warcraft II: Tides of Darkness 1:25:54

Play Pause

3d ago1:25:54

1:25:54

Warcraft II is one of the most influential RTS games of all time. It brought the genre to the mainstream with insane sales, and set the standard for UI and tech trees for years to come. Blizzard had cracked the code on what made RTS games tick, and it laid the groundwork for the classics that would come in its wake. But for all its influence, how m…

1
Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC 11:48

7d ago11:48

11:48

Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. He describes the options available for prophylaxis and how he treats the toxicities that do arise.By Oncololgy News Central

1
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions 14:32

7d ago14:32

14:32

Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a longevity perspective,” explains Sid Devarakonda, MD, director of thoracic medical oncology at Swedish Cancer Institute in Seattle and clinical associate professor at Washi…

1
“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC 12:56

9d ago12:56

12:56

With multiple regimens available for advanced EGFRm NSCLC, selecting the best regimen for an individual patient is key. Jorge Nieva, MD, tells host Aakash Desai, MD, MPH, that the question shouldn’t be about who needs more efficacy, but rather understanding a patient’s personality and goals.By Oncololgy News Central

1
As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty? 15:59

10d ago15:59

15:59

Progress in cancer care means that millions of patients are living longer lives, albeit without hope of a cure. What role can oncologists and other physicians play in helping to navigate these uncertain futures? “What is our obligation to them? How do we understand them and their needs and respond to them?” asks Sunita Puri, MD, author of That Good…

1
Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy? 12:38

1M ago12:38

12:38

A recent study found a link between mRNA vaccination and improved cancer immunotherapy response. The preclinical data demonstrated impressive results, leading to big questions. “We believe that [vaccination] actually does generate and even converts the cold tumors to hot tumors,” Steven H. Lin, MD, PhD, a physician-scientist and radiation oncologis…

1
E135: Yu-Gi-Oh! 5D's World Championship 2011: Over the Nexus 2:08:10

2M ago2:08:10

2:08:10

Yu-Gi-Oh!, along with Magic: The Gathering and Pokemon, is one of the original big 3 trading card games. Starting its life as a Manga, then a tv series, the story about the card game eventually became a card game. Since then Yugioh has morphed through many different iterations and is still going strong today, even if its present self doesn’t have m…

1
Big News From ESMO 2025 Changes Practice in Bladder Cancer 11:39

2M ago11:39

11:39

Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at the European Society of Medical Oncology Annual Congress. “Overall, this is going to change the standard of care for muscle-invasive bladder cancer,” says Amanda Nizam, MD,…

1
Big Changes in AML Care as Targeted Therapy Options Expand 11:09

2M ago11:09

11:09

Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly…

1
E134: Perfect Dark 1:10:25

3M ago1:10:25

1:10:25

Released towards the end of the Nintendo 64’s lifespan in 2000, Perfect Dark was the culmination of several years of FPS development on consoles. After Rare released Goldeneye in 1997, they wanted to take another spin at the formula, but this time with an original IP. Enter Perfect Dark, featuring many of the cornerstones of FPS design that defined…

1
Artificial Sweetener May Impair Cancer Immunotherapy, Raising Broader Questions 16:47

3M ago16:47

16:47

The artificial sweetener sucralose may impair the efficacy of cancer immunotherapy, according to a recent study published in Science. Although further research is needed before these findings can be translated into actionable information for patients, the investigation highlights that “the science of nutrition in cancer is actually quite poor,” say…

1
“Massive Advance” Changes the Chessboard in EGFR-Mutated Metastatic NSCLC 9:54

3M ago9:54

9:54

New survival data from the FLAURA2 and MARIPOSA trials represent “a massive advance for our patients” in terms of frontline treatment for EGFR-mutated non-small cell lung cancer says Sandip P. Patel, MD, professor of medicine at the University of California San Diego. However, the findings have led to new questions about sequencing. “Just like in c…

1
E133: The Legend of Zelda: Ocarina of Time 1:55:28

4M ago1:55:28

1:55:28

The Legend of Zelda: Ocarina of Time is without a doubt one of the most influential video games ever made. Unlike some titles that struggled with the transition to 3D, Zelda absolutely smashed it, setting the blueprint for what successful open world level design looked like for many years to come. It introduced (or popularised) many mechanics, incl…

1
S2 Ep48: Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment 32:01

4M ago32:01

32:01

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; and Matthew P. Goetz, MD, discuss innovations in targeting TROP2 in triple-negative breast cancer treatment. Learning Objectives Upon successful completion…

1
S2 Ep47: Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer—The Evolving Role of Antibody-Drug Conjugates 31:00

5M ago31:00

31:00

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Hope S. Rugo, MD; and Joyce O’Shaughnessy, MD, discuss pivotal trials of antibody-drug conjugates in HR+/HER2- and triple-negative subtypes of metastatic breast cancer. Learning Objectives Upon succ…

1
S2 Ep46: Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer 34:53

5M ago34:53

34:53

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; and Christine M. Lovly, MD, PhD, FASCO, discuss current and emerging treatment strategies targeting HER2 and TROP2 in patients with advance…

1
S2 Ep45: Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies 30:53

5M ago30:53

30:53

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Vinay Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen Bagley, MD, MSCE; and Angela Waanders, MD, MPH, MS; discuss advancements in targeted therapies to treat adult and pediatric low- and high-gra…

1
S2 Ep41: Cases & Conversations™: Transforming AML Care – Precision Strategies, Evolving Therapies, and Clinical Insights 17:15

5M ago17:15

17:15

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; and Amer Zeidan, MBBS, MHS; discuss current best practices and emerging strategies in acute myeloid leukemia (AML) management. Learni…

1
S2 Ep35: Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma 28:30

5M ago28:30

28:30

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treatment options for relapsed/refractory multiple myeloma (R/R MM). Learning Objectives Upon successful completion of this ac…

1
S2 Ep43: GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer 31:30

5M ago31:30

31:30

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Drs Stacey Cohen, Aparna Parikh, Kanwal Raghav, and John Strickler discuss advancements in targeted therapies to treat adult metastatic colorectal cancer. Learning Objectives Upon successful complet…

1
S2 Ep42: Medical Crossfire®: Expert Perspectives on c-MET and MET Targeting in NSCLC—Unveiling the Complexities of MET Dysregulation 48:08

5M ago48:08

48:08

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; and Jeremy Segal, MD, PhD, discuss the emerging data and clinical strategies for targeting c-MET overexpression and MET genomic alterations in …

1
S2 Ep36: Medical Crossfire: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma 35:33

5M ago35:33

35:33

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Mohamad Mohty, MD, PhD and Surbhi Sidana, MD discuss recent advances in treating and managing newly diagnosed multiple myeloma (NDMM). Learning Objectives Upon successful completion of this activity…

1
S2 Ep37: Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing 32:37

5M ago32:37

32:37

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinom…

1
S2 Ep39: Medical Crossfire: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches 21:36

5M ago21:36

21:36

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Gabriela Hobbs, MD; John O. Mascarenhas, MD; and Naveen Pemmaraju, MD; discuss recent advances in therapies for myelofibrosis (MF), polycythemia vera (PV), and essential thrombocytopenia (ET). Learn…

1
S2 Ep38: Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer 32:37

5M ago32:37

32:37

Thank you for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Rachel N. Grisham, MD; Oladapo O. Yeku, MD, PhD, FACP; and Ramez N. Eskander, MD, explore new frontiers in the treatment of ovarian cancer, including advances in biomarker-driven decision-making,…

1
S2 Ep44: PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC – Expert Perspectives on New Approvals and Emerging Strategies 21:10

5M ago21:10

21:10

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; and Misty D. Shields, MD, PhD; discuss recent advances and emerging approaches—including immunotherapy, DLL3-targeted…

1
S2 Ep40: Tumor Board: Expert Insights on Managing Classical EGFR Mutations, EGFR Exon 20 Insertions, and Atypical EGFR Mutations in Metastatic NSCLC 29:28

5M ago29:28

29:28

Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; and Julia Rotow, MD; discuss the latest evidence in managing EGFR-mutated non–small cell lung cancer (NSCLC), with a focus on personalized treatment …

1
Are Oral SERDs About to Transform Breast Cancer Care? 11:29

5M ago11:29

11:29

The development of oral selective estrogen receptor degraders (SERDs) represents substantial progress for patients with metastatic breast cancer who have ESR1 mutations. “I’m extremely excited because they’re the most effective form of endocrine therapy today,” says Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer progra…

1
Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care 10:37

5M ago10:37

10:37

From a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. T…

1
Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology 10:37

6M ago10:37

10:37

Results from the phase 3 ATOMIC trial are practice changing for colorectal cancer care and raise broader questions about immunotherapy use in patients with mismatch repair deficiencies across tumor types. Frank A. Sinicrope, MD, a professor of oncology and medicine at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, presented th…

1
E132: Parasite Eve 1:25:52

6M ago1:25:52

1:25:52

Resident Evil changed everything. When originally released in 1996, what was once a niche genre for enthusiasts was now a blockbuster staple in every second home. All of a sudden people were craving zombies, horrifying monsters and disturbing themes. It was so popular that Square, far more known for its more traditional JRPGs, decided to throw its …

1
Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO 9:29

6M ago9:29

9:29

“An increasingly unrealistic set of performance expectations” is putting a strain on oncologist faculty members, says Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO). He discussed the mounting challenges for academic cancer physicians and how ASCO is working to address them with Robert A. Figlin, MD, the interim director…

1
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care 12:23

6M ago12:23

12:23

“For the first 15 years of my career, we had nothing new” in bladder cancer care, said Jonathan E. Rosenberg, MD, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. Now, “the pace of change has been dizzying,” he told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angele…

1
Practice Changing or “Practice Confounding”? Pivotal Breast Cancer Data Raise Big Questions 12:28

6M ago12:28

12:28

Findings from the SERENA-6 trial, which examined switching therapies in patients with breast cancer ahead of disease progression, made headlines during the 2025 American Society of Clinical Oncology Annual Meeting. However, big questions remain. “I don’t know for sure if the approach is practice changing yet. I think the approach is practice confou…

1
NCCN CEO Discusses Guideline Updates, Other Key Initiatives 12:22

6M ago12:22

12:22

From digitizing its guidelines to potential embedding them in EMRs, the National Comprehensive Cancer Network (NCCN) is working to “make the workflow easier and better” for oncologists, Crystal S. Denlinger, MD, FACP, CEO of the NCCN, told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family C…

1
Former National Cancer Institute Director Discusses the Future of Cancer Care 13:08

6M ago13:08

13:08

“Is it time to do something big and different? That’s always a good question to ask,” said W. Kimryn Rathmell, MD, PhD, MMHC, the immediate former director of the National Cancer Institute (NCI) and the current CEO of The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. At the 2025 American Soci…

1
S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 26:04

6M ago26:04

26:04

Episode Description In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS Discus…

1
S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS) 24:46

6M ago24:46

24:46

Episode Description In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Discuss the mechanisms of action, eff…

1
Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia Vera 6:41

6M ago6:41

6:41

A late-breaking abstract presented at the 2025 American Society of Clinical Oncology Annual Meeting (LBA3) showed that rusfertide significantly increased hematocrit control and improved symptoms for patients with polycythemia vera, a chronic leukemia. “We thought if we could use our understanding of iron regulation, then we could change the game a …

1
S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs 26:11

6M ago26:11

26:11

Episode Description In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they del…

1
E131: Ico 1:21:43

6M ago1:21:43

1:21:43

Director Fumeto Ueda has been hailed by many as somewhat of an auteur of the gaming landscape. A creative whose style embraces minimalist desolation. Known best for his work on Shadow of the Colossus, Ueda's directorial debut took place in 2001 with Ico, a boy-meets-girl action-adventure released for the PlayStation 2. Born with horns in a small vi…

1
Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says 11:40

6M ago11:40

11:40

When it comes to building support for cancer research in the current environment, “the message that we have had in our field is a good one. But we may need to craft a better message,” says Robert A. Winn, MD, director and Lipman Chair in Oncology at the Virginia Commonwealth University Massey Cancer Center in Richmond. Dr. Winn lays out a strategy …

1
“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer 9:42

6M ago9:42

9:42

The addition of perioperative durvalumab in gastric and gastroesophageal junction cancer improved event-free survival, according to findings from the MATTERHORN study. “This trial will be an important milestone,” said Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, …

1
What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now? 12:32

7M ago12:32

12:32

Data from the SERENA-6 trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting, have the potential to dramatically change advanced estrogen receptor–positive, HER2-negative breast cancer care, says William J Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine…